Aris is a serial entrepreneur in Biotech and Big Data. He is president and co-founder of Biovista, and participated in the cofounding of Cellzome (acquired by GSK), Anadys (acquired by Roche), RheoGene (acquired by Inrtrexon), and was SVP at Upstate (acquired by Serologicals). Aris also served as the first Chairperson of the Jefferson Corner Group Fund I, an angel investor group in Charlottesville, VA. Aris authored the Industry Trends column for Nature Biotechnology, was a judge for the 2011 Top-10 Innovations of The Scientist, the 2013 Medical Marketing and Media Awards, and the 2014 MIT Enterprise Forum (Greece). Aris also served as the first Editor-in-Chief of the journal Drug Repurposing, Rescue, and Repositioning. Aris has authored about 90 papers and book chapters, presents extensively, and has a passion for sharing experiences with business school students, having given guest talks at Wharton, Columbia, George Washington, and the University of Auckland Business School. His Ph.D. is in biochemistry from Cambridge, UK. In Feb. 2020 he was included in the World’s Top-50 Futurists.
